Weight loss drug Ozempic may now smash these FTSE 100 stocks

The new breed of weight loss treatments may be a big win for the pharmaceutical sector but other FTSE 100 stocks may rue the day.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Female Doctor In White Coat Having Meeting With Woman Patient In Office

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

Even major FTSE 100 stocks aren’t immune to Black Swan events and one of them could be heading their way in the shape of GLP-1 weight loss drugs like Ozempic and Wegovy.

These are the two best known prescription medications for people living with obesity. Their early success has put a rocket under the shares of Danish pharmaceutical company Novo Nordisk, now Europe’s biggest company. Other sectors won’t come out of this so well.

GLP-1 drugs were developed to treat type II diabetes, by helping users reduce blood sugar levels. They suppress appetite by telling the brain you’re full. They also slow digestion, so food takes longer to leave the body. It’s a huge step forward.

Unforeseen consequences

However, it may be a huge step backwards for FTSE 100 companies selling addictive products like sugar, alcohol and tobacco, which could experience a sharp drop in demand among their most avid users.

If I was the CEO of British American Tobacco, Imperial Brands and spirits maker Diageo, I’d be worried. We all know how hard it is to quit smoking. Around 30% of smokers try every year, but few succeed at the first attempt. 

Giving up drinking isn’t easy either. Dry January has made some inroads and younger drinkers are boozing less. There are an estimated 600,000 dependent drinkers in the UK, but less than one in five receive treatment. Now those who want to kick or cut back have another weapon in their armoury. Diageo’s biggest market is the US. Ozempic et al will be huge over there.

There could be a snowball effect too. As more people stop drinking, it will become easier for politicians to crack down on those who do. I’m keen to add Diageo to my portfolio, taking advantage of a 15% drop in its share price over the last year. Now there’s a new threat I hadn’t considered.

Could be a game changer

I did buy consumer goods giant Unilever recently, as its shares looked nicely priced. However, as well as soap and shampoo, Unilever owns Ben & Jerry’s, and we all know how addictive that is. Plus it owns Hellmann’s, Knorr, Magnum and Wall’s.

Associated British Foods could also be at risk. Its grocery brands include Allinson’s, Allied Bakeries, Blue Dragon, Patak’s, Kingsmill, Jordans, Mazola and Silver Spoon. ABF’s sugar business has the capacity to produce some 4.5m tonnes of sugar annually. Will the world be eating as much of it in future? At least ABF has Primark. All those newly slim shoppers will need a new wardrobe.

What about Tesco, Sainsbury’s, Ocado, Marks & Spencer Group? For that matter, what about The Restaurant Group? Greggs?

These are early days. Not everybody will be taking Ozempic. But with the Health Survey for England 2021 estimating 25.9% of adults in England are obese and a further 37.9% are overweight, many will be tempted. It’s something investors in FTSE 100 food, alcohol and tobacco stocks didn’t have to consider a few months ago.

Fortunately, there are plenty of other Footsie stocks that won’t be affected, whatever happens. There are plenty that I’m bullish on right now, too many to mention them all here of course. Make no mistake, I still believe buying shares in quality companies is the best route to wealth generation available to us all!


Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has positions in Unilever Plc. The Motley Fool UK has recommended Associated British Foods Plc, British American Tobacco P.l.c., Diageo Plc, Imperial Brands Plc, J Sainsbury Plc, Novo Nordisk, Ocado Group Plc, Tesco Plc, and Unilever Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Is Burberry ‘back’ as a solid update drives its shares to 17-month highs?

Burberry shares have risen by more than 60% since May's forecast-beating financials. Can the FTSE 250 luxury giant keep rising?

Read more »

Two gay men are walking through a Victorian shopping arcade
Investing Articles

The Burberry share price continues to rise despite falling sales!

Our writer looks at how the Burberry share price responded to the company’s first-quarter trading update, which was released earlier…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

What a crazy day for the share price of this FTSE 250 retailer!

Our writer’s taken time to digest the latest results of the FTSE 250’s Frasers Group. And he likes what he…

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

1 year on from the CrowdStrike IT outage, here’s how the S&P 500 stock has done

S&P 500 stock CrowdStrike tanked last year when the company caused a huge global IT outage. Its performance since then…

Read more »

Mixed-race female couple enjoying themselves on a walk
Growth Shares

Aiming to turn £10k into £20k? Here are 3 FTSE 250 shares for investors to consider

Our writer demonstrates how three vastly different FTSE 250 stocks could all double an investment over a decade – and…

Read more »

Burst your bubble thumbtack and balloon background
Investing Articles

The unanswered billion-dollar question hanging over the Helium One share price!

With the Helium One share price stuck around 1p, our writer tries to answer the question that he reckons every…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

Is the FTSE 100 becoming increasingly disconnected from the UK economy?

The FTSE 100's broken through the 9,000 barrier for the first time, yet the British economy's shrinking. Should investors be…

Read more »

Bearded man writing on notepad in front of computer
Investing Articles

I’ve just invested £12.06 in this FTSE 250 stock

Why has a FTSE 250 housebuilder that Stephen Wright's been watching for some time suddenly jumped to the top of…

Read more »